一例利伐沙班相关的自发性血胸。
A case of rivaroxaban associated spontaneous hemothorax.
作者信息
Yıldız İbrahim, Aksu Ebubekir, Özmen Yıldız Pınar Özmen, Gürbak İsmail
机构信息
Department of Cardiology, Osmaniye State Hospital, Osmaniye, Turkey.
Department of Thoracic Surgery, Osmaniye State Hospital, Osmaniye, Turkey.
出版信息
Turk Gogus Kalp Damar Cerrahisi Derg. 2019 Jan 1;27(1):118-120. doi: 10.5606/tgkdc.dergisi.2019.15090. eCollection 2019 Jan.
Abstract
New oral anticoagulants have emerged as an alternative for warfarin for thromboembolic prevention in patients with nonvalvular atrial fibrillation. Although new oral anticoagulants have better compliance and safety margin compared to warfarin, we must be cautious with their usage. In this article, we report a case of spontaneous hemothorax related to rivaroxaban treatment. According to our research, this is the first case of spontaneous hemothorax secondary to rivaroxaban treatment.
摘要
新型口服抗凝药已成为华法林的替代药物，用于非瓣膜性心房颤动患者的血栓栓塞预防。尽管新型口服抗凝药与华法林相比具有更好的依从性和安全边际，但我们在使用时仍须谨慎。在本文中，我们报告了一例与利伐沙班治疗相关的自发性血胸病例。根据我们的研究，这是首例继发于利伐沙班治疗的自发性血胸病例。
相似文献
1
A case of rivaroxaban associated spontaneous hemothorax.一例利伐沙班相关的自发性血胸。
Turk Gogus Kalp Damar Cerrahisi Derg. 2019 Jan 1;27(1):118-120. doi: 10.5606/tgkdc.dergisi.2019.15090. eCollection 2019 Jan.
2
Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.达比加群或利伐沙班与维生素K拮抗剂新治疗的非瓣膜性心房颤动患者出血和动脉血栓栓塞事件短期风险的比较：一项法国全国性倾向匹配队列研究。
Circulation. 2015 Sep 29;132(13):1252-60. doi: 10.1161/CIRCULATIONAHA.115.015710. Epub 2015 Jul 21.
3
Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.老年 Medicare 患者口服抗凝药治疗非瓣膜性心房颤动的卒中、出血和死亡率比较。
Am J Med. 2019 May;132(5):596-604.e11. doi: 10.1016/j.amjmed.2018.12.023. Epub 2019 Jan 9.
4
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.非瓣膜性心房颤动患者口服抗凝剂的有效性和安全性。
Stroke. 2018 Dec;49(12):2933-2944. doi: 10.1161/STROKEAHA.118.020232.
5
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).在每日口服一次利伐沙班、直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞试验（ROCKET AF）中，与华法林相比，利伐沙班在老年非瓣膜性心房颤动患者中的疗效和安全性。
Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.
6
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.达比加群、利伐沙班和阿哌沙班与华法林相比治疗非瓣膜性心房颤动的有效性和安全性。
J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725.
7
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动虚弱患者中阿哌沙班、达比加群和利伐沙班与华法林的有效性和安全性。
J Am Heart Assoc. 2018 Apr 13;7(8):e008643. doi: 10.1161/JAHA.118.008643.
8
Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.利伐沙班与华法林用于非瓣膜性心房颤动且伴有严重肾脏疾病或正在接受血液透析的患者。
Am J Med. 2019 Sep;132(9):1078-1083. doi: 10.1016/j.amjmed.2019.04.013. Epub 2019 May 2.
9
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.阿哌沙班与其他口服抗凝剂治疗老年非瓣膜性心房颤动患者的有效性和安全性比较。
Curr Med Res Opin. 2017 Oct;33(10):1745-1754. doi: 10.1080/03007995.2017.1334638. Epub 2017 Aug 29.
10
Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.当代口服抗凝剂在亚洲非瓣膜性心房颤动患者中的疗效和安全性。
Stroke. 2019 Aug;50(8):2245-2249. doi: 10.1161/STROKEAHA.119.025536. Epub 2019 Jun 18.
引用本文的文献
1
Rivaroxaban-induced spontaneous hemothorax: a rare case report and literature review.利伐沙班致自发性血胸：一例罕见病例报告及文献综述
Front Med (Lausanne). 2025 Jul 29;12:1641092. doi: 10.3389/fmed.2025.1641092. eCollection 2025.
2
Sudden hemothorax as a rare initial manifestation of bronchiectasis under a direct oral anticoagulant.
Surg Case Rep. 2022 Sep 23;8(1):175. doi: 10.1186/s40792-022-01536-0.
3
Spontaneous hemothorax caused by concomitant low-dose rivaroxaban and itraconazole in a 95-year-old patient: case report and literature review.95 岁患者同时使用低剂量利伐沙班和伊曲康唑引起的自发性血胸：病例报告及文献复习。
J Int Med Res. 2021 Sep;49(9):3000605211047712. doi: 10.1177/03000605211047712.
本文引用的文献
1
Etiology and management of spontaneous haemothorax.自发性血胸的病因及处理
J Thorac Dis. 2015 Mar;7(3):520-6. doi: 10.3978/j.issn.2072-1439.2014.12.50.
2
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.伴有肝损伤的患者应用口服直接因子 Xa 抑制剂利伐沙班、阿哌沙班和依度沙班以及凝血酶抑制剂达比加群酯的抗凝治疗。
Clin Pharmacokinet. 2013 Apr;52(4):243-54. doi: 10.1007/s40262-013-0034-0.
3
Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.新型口服抗凝剂的实验室评估：方法适用性和不同凝血实验室间的变异性。
Clin Chem. 2013 May;59(5):807-14. doi: 10.1373/clinchem.2012.198788. Epub 2013 Feb 1.
4
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.近期获批的华法林抗凝替代方案对急诊临床医生的综述。
J Emerg Med. 2013 Jul;45(1):143-9. doi: 10.1016/j.jemermed.2012.11.032. Epub 2013 Jan 30.
5
[A rare complication of oral anticoagulant treatment: hemothorax].[口服抗凝剂治疗的一种罕见并发症：血胸]
Tuberk Toraks. 2012;60(1):70-3. doi: 10.5578/tt.2463.
6
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
7
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.肾功能损害对口服直接 Xa 因子抑制剂利伐沙班的药代动力学、药效学和安全性的影响。
Br J Clin Pharmacol. 2010 Nov;70(5):703-12. doi: 10.1111/j.1365-2125.2010.03753.x.
8
Spontaneous hemothorax: a comprehensive review.自发性血胸：综述
Chest. 2008 Nov;134(5):1056-1065. doi: 10.1378/chest.08-0725.
9
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.利伐沙班（一种口服直接Xa因子抑制剂）在健康受试者体内的药代动力学和药效学群体模型。
Int J Clin Pharmacol Ther. 2007 Jun;45(6):335-44. doi: 10.5414/cpp45335.
10
[Hemothorax with high number of eosinophils following warfarin overdose].
Pneumonol Alergol Pol. 2002;70(9-10):496-503.
Zotero 插件